Company: BLRX
Filing Date: 2025-03-31
Form Type: 20-F
Source: 0001178913-25-001123
Chunk: 313

Company: BioLineRx Ltd.
Filing Date: 2025-03-31
Form: 20-F
Item: Item 16A
Chunk 313
---
ITEM 16A. AUDIT COMMITTEE
FINANCIAL EXPERTS

Our board of directors has determined that Mr. Rami Dar is an audit
committee financial expert. Mr. Dar is one of our independent directors for the purposes of the Nasdaq Rules.

ITEM 16B. CODE OF
ETHICS

In July 2011, our board of directors adopted a Code of Business
Conduct and Ethics, or the Code of Conduct, that applies to all our employees, including without limitation our CEO, CFO and controller.
Our Code of Conduct may be viewed on our website at www. biolinerx. com.
The information contained on or through our website, or any other website referred to herein, is not incorporated by reference into this
Annual Report on Form 20-F. A copy of our Code of Conduct may be obtained, without charge, upon a written request addressed to our investor
relations department, 2 HaMa’ayan Street, Modi’in 7177871, Israel (Telephone no. +972-8-642-9100) (e-mail: info@BioLineRx. com).

106

ITEM 16C. PRINCIPAL
ACCOUNTANT FEES AND SERVICES

Fees Paid to Independent Registered Public Accounting Firm

The following table sets forth, for each of the years indicated,
the fees billed by Kesselman & Kesselman, a member firm of PricewaterhouseCoopers International Ltd., our independent registered public
accounting firm.

                              Year Ended December 31,                            
                              2023                                               
 ─────────────────────────────────────────────────────────────────────────────────
  Services Rendered           (in thousands of U. S. dollars)                    
  Audit Fees (1)                                                   130      160  
  Audit-Related Fees (2)                                            17       40  
  Tax Fees (3)                                                      52       41  
  Total                                                            199      211  

  (1)      Audit fees consist of services that would normally be provided in connection with statutory and regulatory         
  (2)      Audit-related services relate to reports to the IIA and work regarding a public listing or offering.               
  (3)      Tax fees relate to tax reports for BioLineRx USA, Inc., tax compliance, planning                                   

Our Audit Committee, in accordance with its charter, reviews and
pre-approves all audit services and permitted non-audit services (including the fees and other terms) to be provided by our independent